1. Home
  2. CNX vs GPCR Comparison

CNX vs GPCR Comparison

Compare CNX & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CNX Resources Corporation

CNX

CNX Resources Corporation

HOLD

Current Price

$41.90

Market Cap

5.5B

Sector

Energy

ML Signal

HOLD

Logo Structure Therapeutics Inc.

GPCR

Structure Therapeutics Inc.

HOLD

Current Price

$63.17

Market Cap

6.3B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNX
GPCR
Founded
1860
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Sector
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
6.3B
IPO Year
1998
2023

Fundamental Metrics

Financial Performance
Metric
CNX
GPCR
Price
$41.90
$63.17
Analyst Decision
Sell
Strong Buy
Analyst Count
9
11
Target Price
$35.78
$104.64
AVG Volume (30 Days)
2.1M
816.4K
Earning Date
04-30-2026
05-29-2026
Dividend Yield
N/A
N/A
EPS Growth
763.33
N/A
EPS
3.98
N/A
Revenue
$2,239,134,000.00
N/A
Revenue This Year
$0.03
N/A
Revenue Next Year
$9.44
N/A
P/E Ratio
$10.48
N/A
Revenue Growth
76.76
N/A
52 Week Low
$27.68
$13.24
52 Week High
$43.12
$94.90

Technical Indicators

Market Signals
Indicator
CNX
GPCR
Relative Strength Index (RSI) 63.15 34.34
Support Level $36.33 $60.42
Resistance Level N/A $72.00
Average True Range (ATR) 1.55 3.33
MACD 0.20 -0.97
Stochastic Oscillator 80.64 21.98

Price Performance

Historical Comparison
CNX
GPCR

About CNX CNX Resources Corporation

CNX Resources Corp is an independent low carbon intensity natural gas and midstream company engaged in the exploration, development, production and acquisition of natural gas properties in the Appalachian Basin. The company's operating segment include Shale and Coalbed Methane. It generates maximum revenue from the Shale segment. It also has other segment that includes nominal shallow oil and gas production.

About GPCR Structure Therapeutics Inc.

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.

Share on Social Networks: